BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33441515)

  • 1. [Immunohistochemical evaluation of BCL-2 expression in acute myeloid leukemia, myeloid sarcoma, and blastic plasmacytoid dendritic cell neoplasm].
    Saika W; Kawahara M; Tashiro H; Teramoto Y; Nagai S; Kumode M; Iwasa M; Asai A; Fujishiro A; Nishimura R; Minamiguchi H; Moritani S; Kito K; Andoh A
    Rinsho Ketsueki; 2020; 61(12):1647-1653. PubMed ID: 33441515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A blastic plasmacytoid dendritic cell neoplasm-like immunophenotype is negatively associated with CEBPA bZIP mutation and predicts unfavorable prognosis in acute myeloid leukemia.
    Song J; Li W; Bai Y; Zhou P; Niu J; Niu X; Liu Y; Liu X; Drokow EK; Sun K; Zhou H
    Ann Hematol; 2024 Feb; 103(2):463-473. PubMed ID: 38183444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients.
    Guolo F; Minetto P; Clavio M; Marcolin R; Miglino M; Passannante M; Caviglia F; Ballerini F; Tedone E; Kunkl A; Mangerini R; Contini P; Colombo N; Cagnetta A; Cea M; Carminati E; Pugliese G; Gobbi M; Lemoli RM
    Leuk Lymphoma; 2020 Jul; 61(7):1695-1701. PubMed ID: 32186422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Wang W; Xu J; Khoury JD; Pemmaraju N; Fang H; Miranda RN; Yin CC; Hussein SE; Jia F; Tang Z; Hu S; Konopleva M; Medeiros LJ; Wang SA
    Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flow Cytometry Identifies a Spectrum of Maturation in Myeloid Neoplasms Having Plasmacytoid Dendritic Cell Differentiation.
    Hamadeh F; Awadallah A; Meyerson HJ; Beck RC
    Cytometry B Clin Cytom; 2020 Jan; 98(1):43-51. PubMed ID: 30614203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm.
    Sangle NA; Schmidt RL; Patel JL; Medeiros LJ; Agarwal AM; Perkins SL; Salama ME
    Mod Pathol; 2014 Aug; 27(8):1137-43. PubMed ID: 24390220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone Marrow.
    Sadigh S; DeAngelo DJ; Garcia JS; Hasserjian RP; Hergott CB; Lane AA; Lovitch SB; Lucas F; Luskin MR; Morgan EA; Pinkus GS; Pozdnyakova O; Rodig SJ; Shanmugam V; Tsai HK; Winer ES; Zemmour D; Kim AS
    Mod Pathol; 2024 Jan; 37(1):100352. PubMed ID: 37839675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review.
    Paluri R; Nabell L; Borak S; Peker D
    Hematol Oncol; 2015 Dec; 33(4):206-11. PubMed ID: 24850172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous blastic plasmacytoid dendritic cell neoplasm occurring after spontaneous remission of acute myeloid leukemia: a case report and review of literature.
    Xie W; Zhao Y; Cao L; Huang W; Wang Y; Huang H
    Med Oncol; 2012 Dec; 29(4):2417-22. PubMed ID: 22476762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmacytoid dendritic cell expansion in myeloid neoplasms: A novel distinct subset of myeloid neoplasm?
    Peng J; He S; Yang X; Huang L; Wei J
    Crit Rev Oncol Hematol; 2023 Dec; 192():104186. PubMed ID: 37863402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison and Development of Immunohistochemical Diagnostic Criteria for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Sakamoto K; Baba S; Okumura Y; Momose S; Ono S; Tonooka A; Ichinohasama R; Takakuwa E; Nakasone H; Ohshima K; Takeuchi K
    Mod Pathol; 2023 Oct; 36(10):100253. PubMed ID: 37380058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
    Egger A; Coello D; Kirsner RS; Brehm JE
    J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous presentation preceding acute myeloid leukemia with CD4+/CD56+ expression misdiagnosed as a blastic plasmocytoid dendritic cell neoplasm: A case report.
    Szablewski V; Costes V; Bret C; Dereure O; Yosr H; Alame M; Cacheux V
    J Cutan Pathol; 2018 Aug; 45(8):610-614. PubMed ID: 29660158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid Cell Nuclear Differentiation Antigen (MNDA) Expression Distinguishes Extramedullary Presentations of Myeloid Leukemia From Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Johnson RC; Kim J; Natkunam Y; Sundram U; Freud AG; Gammon B; Cascio MJ
    Am J Surg Pathol; 2016 Apr; 40(4):502-9. PubMed ID: 26796502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm with Orbital Tumor as the Initial Symptom.
    Li P; Pang N; Li M; Xie J; Wang Y
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.
    Alayed K; Patel KP; Konoplev S; Singh RR; Routbort MJ; Reddy N; Pemmaraju N; Zhang L; Shaikh AA; Aladily TN; Jain N; Luthra R; Medeiros LJ; Khoury JD
    Am J Hematol; 2013 Dec; 88(12):1055-61. PubMed ID: 23940084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare case of blastic plasmacytoid dendritic cell neoplasm with deletion 7q.31, in the setting of heavy pre-treatment with alkylating chemotherapy.
    Kaur V; Swami A; Shebli A; Shalin S; Veeraputhiran M; Emanuel P; Jethava Y
    J Oncol Pharm Pract; 2017 Oct; 23(7):552-556. PubMed ID: 27559020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Beird HC; Khan M; Wang F; Alfayez M; Cai T; Zhao L; Khoury J; Futreal PA; Konopleva M; Pemmaraju N
    Blood Cancer J; 2019 Dec; 9(12):99. PubMed ID: 31811114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case report and literature review.
    Liao H; Yu J; Liu Y; Zhao S; Zhu H; Xu D; Jiang N; Zheng Q
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2911-2919. PubMed ID: 35933443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.